Definition
What is PT-141 or bremelanotide?
PT-141 is the common peptide-clinic name for bremelanotide. The FDA-approved product Vyleesi is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That approval does not automatically extend to men, postmenopausal women, erectile dysfunction, sexual performance, or broad wellness use. Compounded bremelanotide may be discussed in telehealth, but compounded products are not FDA-approved finished drugs.
- The main label concern is a transient rise in blood pressure and reduction in heart rate after use.
- Vyleesi labeling says it is contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Nausea, flushing, headache, vomiting, injection-site reactions, and focal hyperpigmentation are important counseling topics.